Related Experiment Videos
[Blood coagulation inhibitors and thrombosis]
G Lutze1, D Franke, H J Presser
1Institut für Klinische Chemie und Laboratoriumsdiagnostik, Medizinischen Akademie Magdeburg.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|March 1, 1988
Summary
Rare coagulation inhibitors can lead to bleeding or thrombosis. Despite laboratory evidence of inhibition, these conditions do not prevent thrombosis development. Prophylactic factor substitution is not recommended.
Area of Science:
- Hematology
- Coagulation Disorders
Context:
- Pathological coagulation inhibitors present diverse clinical manifestations, including bleeding or thrombosis.
- Lupus inhibitors are a known example of prothrombotic coagulation inhibitors.
Purpose:
- To report on patients with rare coagulation inhibitors exhibiting thrombotic events.
- To analyze the clinical implications of coagulation inhibitors on thrombosis development.
Summary:
- The study describes patients with rare coagulation inhibitors, including a pathological antithrombin and an antithromboplastin, who experienced thromboses.
- Thrombosis occurrence in these patients suggests that coagulation-analytically recognizable inhibition does not always prevent thrombotic events.
- The findings do not support the assumption that these specific inhibitors actively promote thrombosis.
Impact:
- Highlights the complex relationship between coagulation inhibition and thrombotic risk.
- Informs clinical management by indicating that prophylactic factor substitution is not indicated in operative interventions for these patients.